ACIP Presentation Slides: February 22-24, 2023 Meeting

Note: These files are not yet 508

Slides will be added as they become available.

February 22, 2023

Welcome & Introductions

• Introduction
  Dr. G Lee
  Dr. M Wharton

Mpox Vaccine

• Introduction [16 pages]
  Dr. Pablo Sanchez
• Epidemiology of mpox during 2022 outbreak in the United States [18 pages]
  Dr. Sascha Ellington
• JYNNEOS Vaccine Safety [26 pages]
  Dr. Jonathan Duffy
• JYNNEOS Vaccine Effectiveness [21 pages]
  Dr. Anna Chard
• Mpox vaccine acceptability and uptake from cross-sectional surveys [26 pages]
  Dr. Kevin P. Delaney
• Interim Clinical Considerations [12 pages]
  Dr. Rosalind Carter
• EtR: Use of JYNNEOS during mpox outbreaks [48 pages]
  Dr. Agam Rao

Respiratory disease surge, Fall 2022, United States

• Dr. José R. Romero

Influenza Vaccine

• Introduction [3 pages]
  Dr. Keipp Talbot
• U.S. Influenza activity update [7 pages]
  Dr. Lisa Grohskopf
• Preliminary 2022-23 influenza vaccine effectiveness: CDC networks [25 pages]
  Ms. Samantha Olson, Dr. Nathaniel Lewis, Dr. Mark Tenforde
• Preliminary 2022-23 influenza vaccine effectiveness: Wisconsin [15 pages]
  Dr. Huong McClean
• Published Estimates of LAIV Effectiveness [4 pages]
  Dr. Lisa Grohskopf

Pneumococcal Vaccines

• Introduction [9 pages]
  Dr. Katherine Poehling
• Epidemiology of pneumococcal disease among U.S. children [21 pages]
  Mr. Ryan Gierke
• Estimating the impact of higher-valency PCVs on pediatric outpatient ARI visits and antibiotic use [27 pages]
  Ms. Laura King
• PCV20 Phase 2/3 study results among children [18 pages]
  Dr. Wendy Watson
• Preliminary EtR (incl. GRADE) for PCV20 use in U.S. children [57 pages]
  Dr. Miwako Kobayashi
• Workgroup considerations [12 pages]
  Dr. Miwako Kobayashi

February 23, 2023

Welcome & Introductions

• Introduction
  Dr. G Lee
  Dr. M Wharton

Agency Updates

Meningococcal Vaccines

• Introduction [8 pages]
  Dr. Kathy Poehling
  
• Epidemiology of meningococcal disease in the United States [17 pages]
  Ms. Amy Rubis
• Pfizer pentavalent meningococcal vaccine [26 pages]
  Dr. Jason Maguire
• Workgroup considerations [15 pages]
  Dr. Sam Crowe

Polio Vaccine

• Introduction [2 pages]
  Dr. Oliver Brooks
• Recommendations for Adult Polio Vaccination [29 pages]
  Dr. Sarah Kidd

RSV Vaccines – Pediatric/Maternal

• Introduction [5 pages]
  Dr. S Long
• Cost effectiveness analysis for nirsevimab – CDC model [51 pages]
  Dr. David Hutton
• Cost effectiveness analysis for nirsevimab – Comparison to manufacturer model [25 pages]
  Dr. Ismael Ortega Sanchez
• Evidence to Recommendations framework for nirsevimab [92 pages]
  Dr. Jefferson Jones
• Clinical considerations for nirsevimab [16 pages]
  Dr. Jefferson Jones
• Safety and Efficacy of RSV Bivalent PreF Maternal Vaccine [31 pages]
  Dr. Iona Munjal
• Workgroup considerations [6 pages]
  Dr. Katherine Fleming-Dutra

RSV Vaccines – Adult

• Introduction [8 pages]
  Dr. Camille Kotton
• Cost effectiveness of the GSK and Pfizer vaccines (main CDC model) [37 pages]
  Dr. David Hutton
• Comparison of cost effectiveness results of the main CDC model and each manufacturer model (GSK & Pfizer) [24 pages]
  Dr. Ismael Ortega Sanchez
• EtR (incl. GRADE) for 2 vaccines (GSK & Pfizer) [90 pages]
  Dr. Michael Melgar
• Vaccine policy questions (GSK & Pfizer) [2 pages]
  Dr. Michael Melgar

Chikungunya Vaccine

• Introduction [7 pages]
  Dr. Beth Bell
• Global epidemiology of chikungunya [12 pages]
  Dr. Susan Hills
• Chikungunya in U.S. travelers [15 pages]
  Ms. Nicole Lindsey
• Persistent arthralgia following chikungunya [21 pages]
  Ms. Nicole Lindsey
• Workgroup considerations [4 pages]
  Ms. Nicole Lindsey

Dengue Vaccines

• Introduction [8 pages]
  Dr. W Chen
• Takeda dengue vaccine (TAK-003) safety and efficacy [26 pages]
  Dr. Shibidas Biswal
• Workgroup considerations [22 pages]
  Dr. Gabriela Paz-Bailey

Varicella

• Public health impact of 25 years of varicella vaccination in the United States [23 pages]
  Dr. Mona Marin

February 24, 2023

Welcome & Introductions

• Introduction
  Dr. G Lee
  Dr. M Wharton

COVID-19 Vaccines

• Introduction [7 pages]
  Dr. Matthew Daley
• COVID-19 vaccine safety updates: CDC [43 pages]
  Dr. Tom Shimabukuro
• COVID-19 vaccine safety updates: FDA [17 pages]
  Dr. Richard Forshee
• VaST summary [10 pages]
  Dr. Keipp Talbot
• WG interpretation and summary [19 pages]
  Dr. Evelyn Twentyman
• Updates on COVID-19 hospitalizations: COVID-NET [14 pages]
  Dr. Chris Taylor
• Updates to COVID-19 vaccine effectiveness in the United States [29 pages]
  Dr. Amadea Britton
• Considerations for transitioning to bivalent primary series [32 pages]
  Dr. Sara Oliver
• Benefit/risk for COVID-19 vaccines [21 pages]
  Dr. Megan Wallace
• COVID-19 vaccines: future directions [37 pages]
  Dr. Sara Oliver